Business Wire

Postgraduate Institute for Medicine, in Partnership with RMEI Medical Education, Announces an Educational Awareness Campaign for World Arthritis Day

Del

Postgraduate Institute for Medicine (PIM) and RMEI Medical Education (RMEI) have launched the first in a three-part series of global medical education interventions to address ongoing gaps in clinical practice, and to raise awareness for World Arthritis Day by focusing on the importance of early diagnosis and access to evidence-based treatment in rheumatoid arthritis (RA). The partners hope the first activity will stimulate professional reflection on practice behavior and patient outcomes, while later content will address emerging data on therapeutic pathways and patient engagement.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171012005711/en/

The series is entitled Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes, and will incorporate alternating cycles of education, assessment, and recalibration of content to meet evolving healthcare provider needs.

“If pharmacological treatment for rheumatoid arthritis is started within 12 weeks after the onset of symptoms, this could minimize the level of joint impact over time and increase the chances of remission1,” noted Dr. Jeffrey Curtis, professor of medicine and director of the Arthritis Clinical Intervention Program at the University of Alabama at Birmingham, in the United States. “Both EULAR and ACR guidelines advocate for a treat-to-target approach with shared decision making. There has been a general failure to adopt this in clinical practice, and the weight of the evidence is that these approaches work to optimize care for patients with RA.”

Each of the 3 online courses will present learners with unique educational environments: the first, called Clinical Reflections™, uses a virtual clinical setting to allow learners to rethink decisions based on realistic patient care scenarios and to modify their management plans accordingly to affect behavioral change. The second, Clinical Convergence ®, engages learners by integrating video patient perspectives with clinical content to illustrate potential differences between clinician and patient perceptions of their care. The third and final course, Clinical Conversations™, teaches clinicians certain technical skills and a step-wise process for integrating shared decision-making into patient care, a core competency not taught extensively in medical school and not appropriately utilized by clinicians in various specialties and disciplines.

Supported by independent educational grant funding from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals, this advanced analytics-driven initiative is the first of its kind in the RA education field.

“Why this is important to patients with RA might seem obvious, since clinicians who engage in RA-related education tailored to specific drivers of educational need tend to improve the care they deliver to their patients,” said Jacqui Brooks, MBBCh, MRCPsych, Senior Vice President of Medical Strategy at RMEI. “Our research has shown that proactive monitoring of disease activity and selecting appropriate treatment options – particularly in patients with moderate to severe disease – as well as use of shared decision-making approaches, are areas of particular deficit. The Learner Pathway in RA will address these issues with laser-like focus.”

This initiative has been planned to support EULAR’s “Don’t Delay, Connect Today” campaign, an initiative for uniting the voices of People with Arthritis and Rheumatism (PARE) organizations, scientific member societies, and health professional associations, with the united goal of highlighting the importance of early diagnosis and access to treatment.

About RMEI Medical Education
Founded in 1990, RMEI Medical Education (RMEI) is one of the longest operating medical education companies in the US. With an emphasis on sophisticated learner analytics for program design, delivery, and assessment, RMEI works to elevate the dialogue on what makes for effective education. In designing innovative teaching modalities such as the Clinical Convergence™ platform for its 5 primary therapeutic areas, RMEI seeks to inspire greater collaboration within the care team and stronger commitment to patient engagement. For more information, visit www.rmei.com, call 856-672-3152, or e-mail at contact@rmei.com.

About EULAR
The European League Against Rheumatism (EULAR) is a pan-European, non-profit organization that represents people with arthritis/rheumatism, health professionals in rheumatology, and scientific societies of rheumatology across Europe. EULAR aims to reduce the burden of rheumatic and musculoskeletal diseases (RMDs) on the individual and society and to improve the treatment, prevention, and rehabilitation of them. It promotes the translation of research advances into improved daily care for people with RMDs, and fights for governing bodies in Europe to recognize the needs of people with RMDs.

EULAR’s members include scientific societies, health professional associations, patient organizations, corporate members and people with RMDs across Europe. 2017 marks the 70th anniversary of EULAR, marking 70 years of research and the collaboration between physicians, health professionals, and patients. For more information, please visit www.eular.org.

1 Van der Linden MP, le Cessie S, Raza K, et al. Long-Term Impact of Delay in Assessment of Patients with Early Arthritis. Arthritis Rheum. 2010;62(12):3537-3546.

Contact information

RMEI Medical Education
Dave Clausen, CHCP, 856-672-3152
contact@rmei.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Interactive Brokers Launches Bitcoin Futures Trading at the Start of Trading December 10th, 201711.12.2017 16:28Pressemelding

Interactive Brokers Group, Inc. (NASDAQ GS:IBKR), a global electronic brokerage firm, began offering clients the ability to trade bitcoin futures at the start of trading on the Cboe Futures Exchange (CFE) on Sunday night, December 10th, 2017. In addition to offering bitcoin futures from the CFE, under the ticker symbol GXBT, the company plans to offer bitcoin futures from the Chicago Mercantile Exchange (CME) at the scheduled start of trading December 18th using the symbol BRR. IBKR was there at the start of trading and its systems operated normally. “Interactive Brokers was on the buy side of the low print of 14,710,” said Thomas Peterffy, founder, Chairman and CEO of Interactive Brokers. “A Registered Investment Advisor on the Interactive Brokers platform purchased two March contracts in the first minute of trading.” As of 9:15am ET on Monday, the company said that

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00Pressemelding

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice

Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47Pressemelding

The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i

Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18Pressemelding

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,

Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 09:41Pressemelding

The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr

Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 08:00Pressemelding

The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom